1. Home
  2. TFIN vs ZYME Comparison

TFIN vs ZYME Comparison

Compare TFIN & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TFIN

Triumph Financial Inc.

HOLD

Current Price

$57.46

Market Cap

1.5B

Sector

Finance

ML Signal

HOLD

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$24.77

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TFIN
ZYME
Founded
1981
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.8B
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
TFIN
ZYME
Price
$57.46
$24.77
Analyst Decision
Hold
Strong Buy
Analyst Count
5
11
Target Price
$63.00
$38.90
AVG Volume (30 Days)
197.1K
654.9K
Earning Date
04-15-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.33
EPS
N/A
N/A
Revenue
N/A
$105,965,000.00
Revenue This Year
$7.27
$162.82
Revenue Next Year
$11.31
N/A
P/E Ratio
$66.31
N/A
Revenue Growth
N/A
38.87
52 Week Low
$42.90
$9.03
52 Week High
$77.84
$28.49

Technical Indicators

Market Signals
Indicator
TFIN
ZYME
Relative Strength Index (RSI) 45.68 56.49
Support Level $53.63 $24.79
Resistance Level $61.97 $27.54
Average True Range (ATR) 1.89 1.20
MACD 0.35 0.04
Stochastic Oscillator 59.46 43.27

Price Performance

Historical Comparison
TFIN
ZYME

About TFIN Triumph Financial Inc.

Triumph Financial Inc is a financial holding company. The company has four reportable segments namely Banking, Factoring, Payments, and Intelligence. The Banking segment includes the operations of TBK Bank. The Factoring segment includes the operations of Triumph Financial Services with revenue derived from factoring services, The Payments segment includes the operations of TBK Bank's TriumphPay division which provides a presentment, audit and payment solution to Shipper, Broker, and Factor clients in the trucking industry and The Intelligence segment includes to turn the over-the-road trucking data collected through the services into actionable insights for their customers.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: